Khwaja A, Mills W, Leveridge K, Goldstone A H, Linch D C
Department of Haematology, University College London Medical School, UK.
Bone Marrow Transplant. 1993 Jun;11(6):479-82.
Granulocyte colony-stimulating factor (G-CSF) has been shown to be effective in accelerating neutrophil recovery after BMT. In this single centre study, we have examined the effect of delaying the start of treatment with G-CSF (5 micrograms/kg) until 8 days after BM infusion in a cohort of 17 patients with malignant lymphomas undergoing autologous BMT. In comparison with historical controls, neutrophil recovery to > 0.5 x 10(9)/l was shortened from 22 to 14 days (p < 0.01). Patients receiving G-CSF required iv antibiotics for a median 13 days (control 17, p < 0.05) and were discharged a median 28 days post-ABMT (control 32.5, p = NS). Patients received G-CSF for a median of 10 days only. Although these results require confirmation in a randomised trial they suggest that G-CSF administration could be delayed until 8 days after BMT without compromising efficacy and with an accompanying reduction in treatment costs.
粒细胞集落刺激因子（G-CSF）已被证明在加速骨髓移植后中性粒细胞恢复方面有效。在这项单中心研究中，我们研究了在17例接受自体骨髓移植的恶性淋巴瘤患者中，将G-CSF（5微克/千克）治疗开始时间推迟至骨髓输注后8天的效果。与历史对照相比，中性粒细胞恢复至>0.5×10⁹/升的时间从22天缩短至14天（p<0.01）。接受G-CSF治疗的患者静脉注射抗生素的中位时间为13天（对照组为17天，p<0.05），自体骨髓移植后中位出院时间为28天（对照组为32.5天，p=无显著差异）。患者接受G-CSF的中位时间仅为10天。尽管这些结果需要在随机试验中得到证实，但它们表明G-CSF给药可以推迟至骨髓移植后8天，而不会影响疗效，同时还能降低治疗成本。
